Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background Immune checkpoint inhibitors (ICIs) have been increasingly used in cancer treatment, and a subset of patients undergo pseudoprogression. Recognizing the incidence of pseudoprogression is critical for clinical practice. Purpose To evaluate by systematic review and meta-analysis the incidence of pseudoprogression in cancer treatment with ICIs, and compare the incidence according to response criteria, tumor types, and immunotherapeutic agents. Materials and Methods Medline and Embase were searched to identify relevant studies published before December 31, 2018. Clinical trials, post hoc analysis of clinical trials, and prospective studies on ICI treatment in patients with malignant solid tumors were included. Pooled incidence of pseudoprogression for all included studies, per definition of pseudoprogression, cancer type, and drug type, was obtained by random-effects models with inverse variance weighting model. Results Seventeen studies with 3402 patients were analyzed. The pooled incidence of pseudoprogression was 6.0% (95% confidence interval: 5.0%, 7.0%). The definition of pseudoprogression were divided into four categories: progressive disease followed by partial response (PR) or complete response (CR) but not stable disease (SD) with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (six studies); progressive disease followed by SD or PR or CR with RECIST 1.1 (five studies); progressive disease followed by SD or PR or CR with RECIST 1.0 (three studies); and progressive disease followed by SD or PR or CR with immune-related response criteria (irRC) (three studies). Incidence of pseudoprogression varied from 4.5% to 8.0% per definition, ranged from 5.0% to 7.0% per cancer type, and was 5.6% with the monotherapy of programmed cell death-1 inhibitor. Conclusion The overall incidence of pseudoprogression was 6.0% and was less than 10% in subgroup analyses according to the definitions of pseudoprogression, cancer type, and immune checkpoint inhibitor type. Varying definitions across trials and studies indicates the need for uniform criteria of pseudoprogression for solid tumors. © RSNA, 2020 Online supplemental material is available for this article. See also the article by Dodd and MacDermott in this issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the accumulating evidence of 'pseudoprogression' in a minority of ICB recipients 62”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Research works printed but not linked: 1
- 10. Identifying Markers for Clinical Outcome and Treatment Decisions. Clin Cancer Res 2017;23(16):4671-4679.
Cited by
Items 101–177 of 177
A Wake-Up Call for Immune Checkpoint Inhibitor–Related Pneumonitis
Lee, H. Y. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.001 · Cited by 2
Hypothesis: AdAPT-001 and pseudoprogression – when seeing is not necessarily believing
Conley, A. P., Larson, C., Oronsky, B. T., Stirn, M., Caroen, S. Z., & Reid, T. R. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008809 · Cited by 1
Dhayal, P., Rasool, G., & Pathania, A. (2024) · The Journal of Marketing Theory and Practice · doi:10.1080/10696679.2024.2433532 · Cited by 1
“Park et al. (2020) reported an I2 value of 88.823, indicating a high level of heterogeneity, suggesting that approximately 89% of the total variance in observed effects is attributed to true effects rather than sampling error.”
InfluentialHorisaki, K., Yoshikawa, S., Omata, W., Tsutsumida, A., & Kiyohara, Y. (2025) · The Journal of Dermatology · doi:10.1111/1346-8138.17938 · Cited by 1
“The reported frequency of pseudo-progression in advanced MM treated with ICIs is 6.4%, a figure that aligns well with the findings in this study [19].”
InfluentialCaprioli, C., Morscio, J., Chui, J. S., González‐Blas, C. B., Vandereyken, K., Voet, T., Antoranz, A., Vleeschouwer, S. D., Clement, P., Bosisio, F. M., et al. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00053-9 · Cited by 1
Pseudoprogression after CAR T-cell therapy mimicking orbital lymphoma relapse
Miyachi, T., Kitadate, A., & Takahashi, N. (2026) · QJM · doi:10.1093/qjmed/hcag037 · Cited by 1
Zhang, Y., Tian, Y., Wei, X., Bai, L., Song, M., Guo, Y., Liu, T., Li, X., Shan, W., Wu, H., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1659007 · Cited by 1
“Radiologic responses may exhibit delayed manifestation, and pseudoprogression — an occurrence associated with immunotherapy-induced in fl ammatory reactions — can manifest in certain patients (25, 26).”
Franzese, R. C., Qin, L., Fu, S., Rich, B. E., Zografos, E., Zierhut, M. L., & Visser, S. A. G. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70196 · Cited by 1
Miura, R., Ohira, G., Maruyama, M., Tochigi, T., Maruyama, T., Okada, K., Hirata, A., & Matsubara, H. (2026) · Surgical Case Reports · doi:10.70352/scrj.cr.25-0634 · Cited by 1
“10,11) PsP occurs in only 5%–10% of patients and is usually associated with favorable outcomes.”
Yang, J., Qin, Z., Zhou, Z., Liu, J., Chen, L., Mo, Z., Liao, M., Cui, D., Wu, K., Tang, D., et al. (2026) · Thoracic Cancer · doi:10.1111/1759-7714.70288 · Cited by 1
Kunz, W. G., Bonaffini, P. A., Zamboni, G. A., Cappello, G., Leithner, D., & Mayerhoefer, M. E. (2026) · European Radiology · doi:10.1007/s00330-026-12639-9 · Cited by 1
“Although uncommon, pseu-doprogression has been reported in 5 – 10% of patients receiving immune-checkpoint inhibitors, and in about 6% of melanoma patients [12].”
Fountoukidis, G., Tina, E., Eremo, A. G., Ullenhag, G. J., & Valachis, A. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04433-9 · Cited by 1
“The reported frequency of pseudoprogression during immune checkpoint inhibitor therapy ranges from 6 to 10%, depending on the response criteria applied [1–5].”
Liu, T., Lin, J., Li, Y., & Wang, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1893952 · Cited by 1
“CT and MRI measure size changes that lag behind the underlying biology and cannot distinguish immune in fi ltration from true progression (16, 17).”
Nakanishi, Y., Kawashima, Y., Shinohara, M., Hagiwara, K., Inui, K., Ogawa, K., Fujimori, D., Moriyama, S., Oba, H., & Satoshi, S. (2026) · IJU Case Reports · doi:10.1002/iju5.70270 · Cited by 1
Xie, P., Zheng, H., Chen, H., Wei, K., Pan, X., Xu, Q., Wang, Y., Tang, C., Gevaert, O., & Meng, X. (2021) · BMC Cancer · doi:10.1186/s12885-021-08944-9 · Cited by 1
Ren, F., Wang, Y., Gao, Y., & Meng, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.971192 · Cited by 1
Tracheoesophageal Fistula Associated with Nivolumab
Bahadır, A., Yurt, S., Özgül, M. A., Karagöl, M. A., & arafat, L. (2022) · Respiratory Case Reports · doi:10.5505/respircase.2022.70846 · Cited by 1
Lin, Z., Zhan, J., & Zhang, L. (2024) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2023.139 · Cited by 1
Important Points to Consider When Evaluating the Response to Drug Therapy for Lung Cancer
Yabuuchi, H., Kamitani, T., Sagiyama, K., Yamasaki, Y., Hida, T., Matsuura, Y., & Ishigami, K. (2020) · Haigan · doi:10.2482/haigan.60.942
MANAGING CHANGE, CREATIVITY AND INNOVATION: IMPROVING MANAGEMENT SKILLS OF THE DIY ARTIST
Oliver, P. G., & Xian-feng, W. (2012) · INTED proceedings
An Immune-Related Gene Prognostic Index for Bladder CancerPreprint
Liu, S., Wang, Y., Deng, K., Huang, L., Peng, S., Wei, S., & Duan, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1562007/v1
Cavallero, D., BORRI, F., Bruni, L., Chiellini, M., Cioni, D., & Neri, E. (2022) · Journal of Radiological Review · doi:10.23736/s2723-9284.22.00193-3
Authors’ reply to Sahoo, Veniyoor, and Vora
Abraham, G. M., Noronha, V., & Prabhash, K. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_210_21
A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
Hayakawa, N., & Kikuchi, E. (2022) · IJU Case Reports · doi:10.1002/iju5.12510
Radiologic assessment of tumor response to immunotherapy and its complications
Roshkovan, L., & Katz, S. I. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822620-9.00019-7 · Cited by 1
Marqueurs de réponse thérapeutique du mélanome
Nardin, C. (2021) · theses.fr (ABES) · doi:10.70675/3df0a98dz9c72z4558zafaezd0975db0019f · Cited by 1
Li, Q., Cristini, V., Gupta, A. K., Achour, I., Barrett, J. C., & Koay, E. J. (2024) · JCO Clinical Cancer Informatics · doi:10.1200/cci.23.00254
Imaging Correlates of Immune Checkpoint Inhibitors in Cancer Management
Karimi, H., Mohammadi, S., Valizadeh, P., Ebrahimi, S., Roudsari, P. P., Khojasteh‐Kaffash, S., & Keshavarz, E. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_390-1 · Cited by 1
Zhu, Z., Li, L., Zhao, Y., Wang, X., & Zhao, X. (2025) · Research Square · doi:10.21203/rs.3.rs-6116450/v1
Popova, E., Zhelyazkova, Z., Sofiyanski, T., Sergieva, S., & Krasteva, R. (2025) · Preprints.org · doi:10.20944/preprints202504.0510.v1
Harada, Y. (2025) · Drug Delivery System · doi:10.2745/dds.40.108
Kikuta, S., Hattori, C., Abe, Y., Hino, K., Matsuo, K., & Kusukawa, J. (2025) · Oral Diseases · doi:10.1111/odi.70051
“It is well documented that patients treated with ICIs can exhibit atypical response patterns, characterized by a transient increase in tumor burden or the appearance of new lesions, followed by a subsequent decrease (Chiou and Burotto 2015; Wang et al. 2018; Park et al. 2020).”
Pseudoprogression of Non-Small Cell Lung Cancer Following Neoadjuvant Therapy: A Case Report
Ramadan, K., Benaissa, M., & Shackcloth, M. J. (2025) · Cureus · doi:10.7759/cureus.92448
“In a meta-analysis, Park et al. estimated the incidence following immunotherapy is around 6% in solid tumors [5-6].”
Imaging Correlates of Immune Checkpoint Inhibitors in Cancer Management
Karimi, H., Mohammadi, S., Valizadeh, P., Ebrahimi, S., Roudsari, P. P., Khojasteh‐Kaffash, S., & Keshavarz, E. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_390
Zhao, Y., Naidoo, J., Conroy, M. R., Ferri, J. T., Gills, J. J., Chen, K. Y., White, J. R., Glass, S., Assan, W. O., Peloza, K. E., et al. (2025) · medRxiv · doi:10.1101/2025.10.01.25336378
The antitumor mechanism of immuno-flap treatment in a rat model of head and neck cancer
Mori, H., Akiyama, Y., Maeda, C., Kanematsu, A., Ashizawa, T., Yamashita, K., Miyata, H., Iizuka, A., Ikeya, T., Yasunaga, Y., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04208-8
Pseudoprogression bei Immuntherapien
Winkelmann, M., Kassube, M., Linden, P., Rübenthaler, J., Sheikh, G. T., & Kunz, W. G. (2025) · Die Radiologie · doi:10.1007/s00117-025-01544-9
Nebenwirkungen von Immuntherapien: Fokus Abdomen
Bauer, F., & Persigehl, T. (2025) · Die Radiologie · doi:10.1007/s00117-025-01549-4
Mönch, S., Heimer, M. M., Winkelmann, M., Guertler, A., Schlaak, M. S., Tufman, A., Ben Khaled, N., de Toni, E., Westphalen, C. B., von Bergwelt-Baildon, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23435142
Mönch, S., Heimer, M. M., Winkelmann, M., Guertler, A., Schlaak, M. S., Tufman, A., Ben Khaled, N., de Toni, E., Westphalen, C. B., von Bergwelt-Baildon, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23435145
Mönch, S., Heimer, M. M., Winkelmann, M., Guertler, A., Schlaak, M. S., Tufman, A., Ben Khaled, N., de Toni, E., Westphalen, C. B., von Bergwelt-Baildon, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23435169
Mönch, S., Heimer, M. M., Winkelmann, M., Guertler, A., Schlaak, M. S., Tufman, A., Ben Khaled, N., de Toni, E., Westphalen, C. B., von Bergwelt-Baildon, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23435160
Mönch, S., Heimer, M. M., Winkelmann, M., Guertler, A., Schlaak, M. S., Tufman, A., Ben Khaled, N., de Toni, E., Westphalen, C. B., von Bergwelt-Baildon, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23435172
Mönch, S., Heimer, M. M., Winkelmann, M., Guertler, A., Schlaak, M. S., Tufman, A., Ben Khaled, N., de Toni, E., Westphalen, C. B., von Bergwelt-Baildon, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23435151
Xie, P., Zheng, H., Chen, H., Wei, K., Pan, X., Xu, Q., Wang, Y., Tang, C., Gevaert, O., & Meng, X. (2021) · Figshare · doi:10.6084/m9.figshare.17054767
Mönch, S., Heimer, M. M., Winkelmann, M., Guertler, A., Schlaak, M. S., Tufman, A., Ben Khaled, N., de Toni, E., Westphalen, C. B., von Bergwelt-Baildon, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23435154
Mönch, S., Heimer, M. M., Winkelmann, M., Guertler, A., Schlaak, M. S., Tufman, A., Ben Khaled, N., de Toni, E., Westphalen, C. B., von Bergwelt-Baildon, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23435163
Xie, P., Zheng, H., Chen, H., Wei, K., Pan, X., Xu, Q., Wang, Y., Tang, C., Gevaert, O., & Meng, X. (2021) · Figshare · doi:10.6084/m9.figshare.17054770
Mönch, S., Heimer, M. M., Winkelmann, M., Guertler, A., Schlaak, M. S., Tufman, A., Ben Khaled, N., de Toni, E., Westphalen, C. B., von Bergwelt-Baildon, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23435175
Mönch, S., Heimer, M. M., Winkelmann, M., Guertler, A., Schlaak, M. S., Tufman, A., Ben Khaled, N., de Toni, E., Westphalen, C. B., von Bergwelt-Baildon, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23435166
Zhuang, X., Zhang, H., Chen, P., Tian, X., Zhang, X., Song, G., Liu, Y., Hua, Y., & Wang, Z. (2025) · Sains Malaysiana · doi:10.17576/jsm-2025-5412-10
Wang, X., Ding, Y., Liu, H., Zhu, C., Qu, X., Kang, Y., Ding, C., Wang, Y., Mao, M., Li, Z., et al. (2026) · Insights into Imaging · doi:10.1186/s13244-025-02196-y
“This approach does not fully consider immunotherapy-induced changes, like lymphocyte in fi ltration into the tumor microenvironment, which may result in pseudoprogres-sion [7].”
Armashi, A. R. A., Gong, J. D., Barata, P. C., Brown, J., Garcia, J. A., & Sheng, I. Y. F. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2628071
Mori, H., Sekine, Y., Kuroda, K., Ueda, S., Saeki, Y., Kobayashi, N., Ichimura, H., Takemura-Kobayashi, N., Matsubara, D., & Sato, Y. (2026) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2026.102388
Imaging of Neoplastic Disease of the Lung
Pinna, A., Saba, L., Polverosi, R., Muzzio, P. C., Vincenzi, M., & Rigoni, B. (2026) · Medical radiology · doi:10.1007/174_2026_686
Liu, Y., Zhou, M., Xi, J., Sun, G., & Wang, Z. (2026) · Translational Cancer Research · doi:10.21037/tcr-2025-aw-2512
“Consequently, initial radiographic assessments may underestimate true therapeutic activity, particularly when relying on conventional RECIST criteria (38).”
Shimoda, M., Ohtake, S., Aoki, T., Karibe, J., Shibata, Y., Imano, M., Inoue, M., & Kobayashi, K. (2026) · IJU Case Reports · doi:10.1002/iju5.70192
Bonini, R. M. (2026) · Radiologia Brasileira · doi:10.1590/0100-3984.2025.0101ed
van Mossel, S., Saing, S., Vriens, D., Bloem, M., Kapiteijn, E., Kersbergen, D., Lopci, E., Koffijberg, H., & de Geus‐Oei, L. (2026) · The EANM Journal · doi:10.1016/j.eanmj.2026.100230
Human and Animal Tumour Efficacy Evaluation: Endpoints and Methods from a Translational Perspective
Chen, Q. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202623702026
Human and Animal Tumour Efficacy Evaluation: Endpoints and Methods from a Translational Perspective
Chen, Q. (2026) · Springer Link (Chiba Institute of Technology) · doi:10.1051/bioconf/202623702026/pdf
Hughes, R. T., Smith, S., Lycan, T. W., Bunch, P. M., D’Agostino, R. B., Frizzell, B. A., Kinney, R. D., Rashid, S., Triozzi, P., Zhang, W., et al. (2026) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2026.1527
Zhang, R., Li, Y., Duan, F., Wang, X., Zhang, M., Li, P., & Wang, D. (2026) · BMC Cancer · doi:10.1186/s12885-026-16372-w
“Moreover, the use of PFS as the primary endpoint may be confounded by pseudoprogression, a phenomenon well-documented in immunotherapy [28].”
Barve, R. (2026) · Applied Radiation Oncology · doi:10.37549/aro-d-26-0008
Withey, S. J., Caglič, I., Dafydd, D. A., WICKI, A. N., Kelly‐Morland, C., Sohaib, A., Sit, C., Remer, E. M., & Kekelidze, M. (2026) · Abdominal Radiology · doi:10.1007/s00261-026-05604-z
Santo, G., Pozzessere, C., Michielin, O. A., Cascini, G. L., Prior, J. O., & Cicone, F. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-08080-1
Advancing Organoid-Interacting Lymphocytes Towards In Vivo Validation for Solid Tumor Treatment
Refaqat, N. E. (2026) · WakeSpace Scholarship (Wake Forest University)
PET/CT Imaging in Melanoma: Review of Current Evidence and Clinical Applications
Giachetti, V. A. M.-B., Serur, I. P., Barbosa, F. D. G., Awni, B. M., Katz, G. F., & Munhoz, R. R. (2026) · Brazilian Journal of Oncology · doi:10.1055/s-0046-1824762
“39 This may produce two possible patterns of apparent progression on initial PET scans, known as pseudoprogression: 39,74 a) a transitory increase in preexisting lesions, followed by shrinking, or b) onset of new lesions, followed by a subsequent reduction in the overall tumor burden.”
Chen, H., Meng, X., Cai, L., Lei, W., Tang, Y., Shi, X., Ma, L., & Zhao, J. (2026) · Translational Lung Cancer Research · doi:10.21037/tlcr-2026-0397
“It is critical to consider the potential confounding effect of pseudoprogression, a phenomenon unique to immunotherapy where initial tumor enlargement or new lesion formation precedes subsequent regression (38).”
Chen, D.-Y., Cao, Z.-Z., & Zhou, S. (2026) · Ear Nose & Throat Journal · doi:10.1177/01455613261480421
Ghais, A., Rizkallah, J., Wehbeh, B. E. D., Diab, Y., Awada, A., Atwi, M., Ayoub, R., Mina, C., Rammal, F., badr, A., et al. (2026) · Cancers · doi:10.3390/cancers18172829
“In a systematic review and meta-analysis of ICI-treated solid tumors, the pooled incidence of pseudoprogression was 6.0% overall and 6.4% in melanoma [26].”
InfluentialCui, H., Piao, Z., & Zhang, S. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1954076
Gilvetmab advances immune checkpoint inhibitor immunotherapy for canine cancer
Chon, E., Greene, L. M., & Stock, M. L. (2026) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.26.06.0517 · Cited by 1
Li, A., Lou, E., Leder, K., & Foo, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.18.752698
“Thus the incidence of PsP [4] may depend partly on clinical sampling times and measurement resolution, and warrants further evaluation in clinical datasets.”
Basher, F., Smith, T. A., Rubinstein, M. P., & Wu, J. D. (2026) · Biomedicines · doi:10.3390/biomedicines14102390
“The transient aggressive tumor growth in mice that received Pmel and cIgG or Pmel and B10G5 prior to tumor regression was likely due to pseudo-progression induced by amplified immune responses at the tumor site [54].”
Kaushik, P., Bhatted, S. K., & Dedge, A. P. (2026) · Ayush journal of integrative oncology. · doi:10.4103/ajio.ajio_23_26
Jeong, D. Y., Whi, W., Park, S., Oh, Y. J., Kim, J., Kim, J., Sun, J., Ahn, J. S., Jung, H. A., Lee, S., et al. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2027.42.e63
Metadata
- Authors
- Park, H. J., Kim, K. W., Pyo, J., Suh, C. H., Yoon, S., Hatabu, H., & Nishino, M.
- Affiliations
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Radiology
- Published
- 2020-10
- Volume
- 297
- Issue
- 1
- Pages
- 87-96
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- PMC
- PMC7526949
- OpenAlex
- W3047211233
- Cited by
- 162
- References
- 45
- Citations by year
- 2026: 31 · 2025: 26 · 2024: 22 · 2023: 31 · 2022: 27 · 2021: 19 · 2020: 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Radiology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Research Foundation of Korea (2017R1A2B3011475)
- National Cancer Institute (R01CA203636)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pseudoprogression, immune checkpoint inhibitors, solid tumors, incidence, RECIST 1.1, immune-related response criteria, PD-1 inhibitors, tumor response assessment, cancer immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Neoplasms, Disease Progression, Response Evaluation Criteria in Solid Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.